Zegbeh Jallah
Stock Analyst at Capital One
(2.99)
# 1,451
Out of 4,911 analysts
24
Total ratings
36.36%
Success rate
120.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $2.04 | +4,801.96% | 2 | Dec 27, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $10.48 | +319.85% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $8.84 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $24.51 | +18.32% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $384 | $13.31 | +2,785.05% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $7.40 | +845.95% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $6.30 | +233.33% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $7.84 | +1,621.94% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.57 | +5,036.19% | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | $10 → $6 | $1.09 | +450.46% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $14.58 | +277.23% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.17 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.50 | +1,509.01% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $600 | $1.82 | +32,867.03% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $2.04
Upside: +4,801.96%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $10.48
Upside: +319.85%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $8.84
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $24.51
Upside: +18.32%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $384
Current: $13.31
Upside: +2,785.05%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $7.40
Upside: +845.95%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $6.30
Upside: +233.33%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $7.84
Upside: +1,621.94%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.57
Upside: +5,036.19%
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $1.09
Upside: +450.46%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $14.58
Upside: +277.23%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $3.17
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.50
Upside: +1,509.01%
Dec 18, 2019
Initiates: Buy
Price Target: $600
Current: $1.82
Upside: +32,867.03%